New Drug Development Pipeline

Biozipcode, Inc. has completed the basic research for the definitive cure treatment of diabetes and its complications in humans (repositioning). For these derivatives, we are proceeding with KIYAN PHARMA Inc. as a candidate.

Furthermore, regarding repositioning, the development through repositioning allows for a potentially quicker progression to Phase 1 clinical trials, which confirm safety and pharmacokinetics in healthy adults, since the safety and pharmacokinetics in humans have already been established for the existing drug. This approach could significantly reduce the development period and costs, which are said to take over 10 years for new drugs.

Additionally, we are also advancing the development of a completely new cure for diabetes and its complications using Biozipcode technology (cell targeting technology).

We are currently creating detailed documentation regarding the details of the pipeline.